医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Manhattan Scientifics’ Unparalleled Cancer Measurement Technology Featured in MD Anderson Presentation

2014年10月08日 PM09:49
このエントリーをはてなブックマークに追加


 

ALBUQUERQUE, N.M.

Senior Scientific LLC, a subsidiary of Manhattan Scientifics, Inc. (OTCQB: MHTX), is currently collaborating with The University of Texas MD Anderson Cancer Center (MDACC) to advance, demonstrate and validate a cancer detection and measurement technology originally developed by Edward R. Flynn, PhD. John D. Hazle, PhD of the MD Anderson Cancer Center recently presented initial results from the collaboration in a poster at the World Molecular Imaging Conference in Seoul, South Korea. The link to the results can be found here - http://www.mhtx.com/wmic/2014-poster.pdf.

The poster concluded that Senior Scientific’s MRX technology “is unparalleled in terms of sensitivity compared to imaging-based ovarian cancer detection methods, such as TVU; thus, it holds promise for detecting ovarian cancer much earlier.”

The poster describes the MRX technology as “(based on unpublished data) it is up to 200 times more sensitive than current imaging technologies.”

The poster also noted that, “Because the technology relies on (NPs) binding to specific cancer cells and is detecting molecular markers, only cancer will presumably be detected with this technology while unbound particles in the vascular space will not be detected. Another advantage of nanomagnetic relaxometry compared to some imaging-based technologies is that it does not expose patients to potentially harmful ionizing radiation and, because this technology is considered to be safe for human use, we expect that human studies could begin within the next five years. Thus, nanomagnetic relaxometry holds promise for detecting ovarian cancer much earlier, which is crucial to increasing survivorship.” The Company hopes to accelerate its FDA submissions.

About Manhattan Scientifics, Inc.

Manhattan Scientifics Inc. (www.mhtx.com) is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.

Forward-looking statement

This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company’s actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

CONTACT

Manhattan Scientifics, Inc. PR & IR
Marvin Maslow,
917-923-3300
Email: marvin@mhtx.com
or
Corporate
Advisory/PR

Fastnet Advisors: Anthony Furey, 631-665-1234
Email:
mtfurey@fastnetadvisors.com
or
Hawk
Associates: Frank Hawkins, 305-451-1888
Email: f.hawkins@hawkassociates.com
or
European
Contact:

Herbert Strauss, +43-316-296-316
Email: herbert
“at” eu-ir.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SpeeDxの販売ネットワークが中東に拡大
  • P&G Sets New Goal to Deliver 25 Billion Liters of Clean Drinking Water to Families in Need Worldwide
  • Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
  • Takeda Receives U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia
  • オクタファルマ・グループが2018年の好業績を発表